W W Grainger Inc vs 10X Genomics Inc — how do they compare? W W Grainger Inc trades at $1,310.8 (market cap $61.32B), while 10X Genomics Inc trades at $57.04 (market cap $7.61B). The key difference: W W Grainger Inc is far larger — about 8.1× 10X Genomics Inc's market cap, and W W Grainger Inc pays a 0.77% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| GWW | TXG | |
|---|---|---|
Market Cap | $61.32B | $7.61B |
Sector | Technology | Health |
52-Week High | $1.40K | $58.57 |
52-Week Low | $918.18 | $11.34 |
Enterprise Value | $63.53B | $7.14B |
Dividend Yield | 0.77% | — |
Signals from Pluang's Aura AI — not financial advice
W.W. Grainger (GWW) trades at $1,308.06, up 0.82% on the day, with strong recent earnings beats in Q1 and Q2 2026. The stock shows a bearish technical signal despite robust fundamentals, including a 47.92% ROE and rising revenue. Analysts maintain a cautious stance with a consensus price target of $1,320, while recent news highlights operational strength and market share gains.
Outlook remains mixed; solid earnings growth and margin expansion support upside, but high valuation multiples and bearish technicals pose near-term risks. Investors should weigh strong cash flow and dividend stability against potential volatility from macroeconomic pressures.
TXG (10x Genomics) trades at $56.95, down 2.77% on the day. The stock exhibits bullish technical signals with strong moving averages, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and a narrowing net loss margin from -41.23% in 2023 to -12.18% in 2026. Recent news highlights collaborations with Cleveland Clinic and acquisition of Proteintech Genomics, expanding multiomics capabilities.
Outlook: Growth potential exists through market expansion and innovation, but risks include persistent unprofitability and high valuation multiples. Analyst sentiment is mixed with a $46 consensus target below current price, indicating caution despite recent operational improvements.
Trailing returns across standard periods
Latest headlines on both assets
Grainger is a leading broad-line distributor of maintenance, repair, and operating (MRO) products. It serves millions of customers worldwide through an integrated network of branches and digital platforms.
Read more on GWW →10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →